Small-molecule inhibition of γ-glutamyl carboxylase reveals a novel anticoagulant strategy

Oral anticoagulants such as warfarin, which function as vitamin K antagonists (VKAs), have long been central to anticoagulation therapy. Warfarin inhibits vitamin K epoxide reductase (VKOR), thus restricting the availability of reduced vitamin K and impairing the γ-carboxylation and activation of vitamin K-dependent clotting factors (VKDCFs). However, warfarin's clinical use is hindered by a narrow therapeutic index and marked interindividual variability, largely attributable to genetic variation in VKOR, yet it remains the only oral anticoagulant option for clinical conditions like antiphospholipid antibody syndrome. γ-Glutamyl carboxylase (GGCX), the enzyme that directly modifies VKDCFs, represents an attractive yet largely unexplored target for anticoagulation. Through a cell-based high-throughput screen of the Maybridge Hit-Finder compound library (comprising 14,400 drug-like molecules), we identified 21 compounds that inhibited γ-carboxylation of VKDCFs. Subsequent gene-deficient cell-based assays and in vitro enzymatic characterization revealed that compound HF13141-H5 selectively and potently inhibits GGCX activity, with nanomolar half-maximal inhibitory concentrations. Molecular docking with the recently resolved GGCX structure suggested that HF13141-H5 mimics the binding of reduced vitamin K, and site-directed mutagenesis confirmed the critical hydrogen bond with residue N290 within the substrate-binding pocket. Importantly, HF13141-H5 maintained full inhibitory potency against VKOR variants associated with warfarin resistance and demonstrated robust anticoagulant activity in a zebrafish laser-induced endothelial injury model. In summary, we describe the discovery and mechanistic characterization of HF13141-H5 as the first small-molecule GGCX inhibitor. By directly targeting GGCX, HF13141-H5 presents a promising strategy for developing next-generation anticoagulants that could overcome the limitations of warfarin, including genetic variability and resistance.

Authors

Institutions

Publication Details

Journal
Blood Advances
Published
2025-12-22
DOI
https://doi.org/10.1182/bloodadvances.2025018776
Primary Topic
Vitamin K Research Studies
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Small-molecule inhibition of γ-glutamyl carboxylase reveals a novel anticoagulant strategy

Qing Cao, Catherine E. Richter, Jordan A. Shavit, Shixia Dong et al.
Blood Advances
Vitamin K Research Studies
article

Small-molecule inhibition of γ-glutamyl carboxylase reveals a novel anticoagulant strategy

Qing Cao, Catherine E. Richter, Jordan A. Shavit, Shixia Dong, Yan Shen, H. L. Liu, Dan Song, Zhenyu Hao, S Li, Xuejie Chen, DW Stafford, Jian-Ke Tie, Yiming Guo, Guomin Shen
article en

Abstract

Oral anticoagulants such as warfarin, which function as vitamin K antagonists (VKAs), have long been central to anticoagulation therapy. Warfarin inhibits vitamin K epoxide reductase (VKOR), thus restricting the availability of reduced vitamin K and impairing the γ-carboxylation and activation of vitamin K-dependent clotting factors (VKDCFs). However, warfarin's clinical use is hindered by a narrow therapeutic index and marked interindividual variability, largely attributable to genetic variation in VKOR, yet it remains the only oral anticoagulant option for clinical conditions like antiphospholipid antibody syndrome. γ-Glutamyl carboxylase (GGCX), the enzyme that directly modifies VKDCFs, represents an attractive yet largely unexplored target for anticoagulation. Through a cell-based high-throughput screen of the Maybridge Hit-Finder compound library (comprising 14,400 drug-like molecules), we identified 21 compounds that inhibited γ-carboxylation of VKDCFs. Subsequent gene-deficient cell-based assays and in vitro enzymatic characterization revealed that compound HF13141-H5 selectively and potently inhibits GGCX activity, with nanomolar half-maximal inhibitory concentrations. Molecular docking with the recently resolved GGCX structure suggested that HF13141-H5 mimics the binding of reduced vitamin K, and site-directed mutagenesis confirmed the critical hydrogen bond with residue N290 within the substrate-binding pocket. Importantly, HF13141-H5 maintained full inhibitory potency against VKOR variants associated with warfarin resistance and demonstrated robust anticoagulant activity in a zebrafish laser-induced endothelial injury model. In summary, we describe the discovery and mechanistic characterization of HF13141-H5 as the first small-molecule GGCX inhibitor. By directly targeting GGCX, HF13141-H5 presents a promising strategy for developing next-generation anticoagulants that could overcome the limitations of warfarin, including genetic variability and resistance.

Blood Advances
University of North Carolina at Chapel Hill (US), Harbin Medical University (CN), Henan University of Science and Technology (CN), University of Michigan (US), Michigan United (US), Second Affiliated Hospital of Harbin Medical University (CN), Yangzhou Vocational University (CN), Yangzhou University (CN), Nanjing Medical University (CN)
National Natural Science Foundation of China, China Postdoctoral Science Foundation, Government of Jiangsu Province, Natural Science Foundation of Jiangsu Province, National Institutes of Health, McDonnell Center for Systems Neuroscience
Openalex Percentile: Top 36%
Vitamin K Research Studies
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.